This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "parkinsonism_dopaminergic_degeneration#Nigrostriatal Dopaminergic Neurodegeneration", the key conformance target). It models the dopaminergic final common pathway of parkinsonism (HP:0001300) and is intended for Parkinson disease and the secondary/genetic parkinsonisms — drug- and toxin-induced parkinsonism (MPTP, manganese/manganism), and monogenic forms. The environmental neurotoxicants (rotenone, paraquat, MPTP, manganese) plug into the Mitochondrial Complex I Inhibition and Oxidative Stress node. Two intentional caveats: (1) alpha-synuclein/Lewy pathology is characteristic of Parkinson disease and the synucleinopathies but is not universal — MPTP and rotenone act primarily through complex I inhibition, so conforming nodes may omit the alpha-synuclein arm; (2) manganism is a partial exception in which the predominant lesion is in the globus pallidus rather than the nigrostriatal dopaminergic system, and it characteristically responds poorly to levodopa, yet it still converges on basal-ganglia motor-circuit dysfunction. This module is distinct from tauopathy-predominant atypical parkinsonism (e.g., progressive supranuclear palsy) and from the TDP-43 proteinopathy module.
Dopaminergic Neuronal Vulnerability and Toxic Insult
trigger
The shared initiating event is injury to the dopaminergic neurons of the substantia nigra pars compacta by converging genetic and environmental insults. Epidemiological and toxicological data implicate occupational and environmental neurotoxicants — the herbicide paraquat, the pesticide rotenone, the meperidine contaminant MPTP, and manganese — alongside monogenic causes, all targeting the same selectively vulnerable nigral dopaminergic population.
Downstream
-
Mitochondrial Complex I Inhibition and Oxidative Stress
Toxic and genetic insults converge on mitochondrial complex I inhibition and oxidative stress in dopaminergic neurons.
Show evidence (2 references)
"meta-analysis showed an association between PD and paraquat exposure (odds ratio = 1.64 (95% CI: 1.27-2.13"
Meta-analysis quantifies the environmental-toxicant contribution to the module: paraquat exposure is significantly associated with Parkinson disease, supporting toxic insult to dopaminergic neurons as a conserved trigger.
"Mn accumulation and neurodegenerative diseases such as manganism, Alzheimer's disease, Parkinson's disease, Huntington's disease"
Establishes manganese as an environmental metal whose accumulation is linked to parkinsonian (manganism) and other neurodegenerative disease, supporting metal exposure as a toxic trigger feeding this pathway.
Mitochondrial Complex I Inhibition and Oxidative Stress
amplifier
The convergent biochemical lesion is impairment of mitochondrial electron transport chain complex I with consequent oxidative stress. Environmental parkinsonian toxins act here directly — MPTP (via MPP+), rotenone, and paraquat inhibit or poison complex I — while monogenic PD genes (PINK1, PRKN, DJ-1) compromise mitochondrial quality control. The energy deficit and reactive oxygen species generation render the highly metabolically demanding nigral dopaminergic neurons selectively vulnerable. This node is where the environmental exposome plugs into the module.
Downstream
-
Alpha-Synuclein Aggregation and Lewy Pathology
Oxidative and bioenergetic stress promotes alpha-synuclein misfolding and aggregation in the synucleinopathy forms.
-
Nigrostriatal Dopaminergic Neurodegeneration
Complex I inhibition and oxidative stress directly drive death of vulnerable nigral dopaminergic neurons.
Show evidence (3 references)
"rotenone, the classical inhibitor of mitochondrial complex I. Rotenone triggers the progressive death of dopaminergic neurons and α-synuclein inclusions formation in rats"
The rotenone model directly demonstrates that environmental complex I inhibition is sufficient to produce progressive dopaminergic neuron death and alpha-synuclein inclusions, anchoring the toxin-to-mitochondria edge.
"abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease"
Confirms mitochondrial dysfunction as a shared cellular feature across both monogenic and sporadic disease, supporting it as the convergent node where genetic and environmental causes meet.
"mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease."
Supports the central, long-standing role of mitochondrial dysfunction in parkinsonian neurodegeneration.
Alpha-Synuclein Aggregation and Lewy Pathology
central effector
In Parkinson disease and the synucleinopathy forms of parkinsonism, misfolded alpha-synuclein accumulates into Lewy bodies and Lewy neurites that spread in a prion-like manner and amplify dopaminergic injury. This proteostatic arm is characteristic of Parkinson disease but is not universal across all parkinsonisms — toxin models such as MPTP can produce nigral degeneration with variable alpha-synuclein pathology — so conforming nodes may include or omit it.
Downstream
-
Nigrostriatal Dopaminergic Neurodegeneration
Alpha-synuclein aggregation amplifies degeneration of nigral dopaminergic neurons.
Show evidence (2 references)
"Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein."
Establishes aggregated alpha-synuclein deposition as a defining feature of Parkinson disease pathogenesis, the prototype of this node.
"Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."
Identifies alpha-synuclein inclusions alongside nigral neuronal loss as the paired neuropathological hallmarks, linking the proteostatic arm to dopaminergic neurodegeneration.
Nigrostriatal Dopaminergic Neurodegeneration
effector
The convergent effector lesion is progressive degeneration of the substantia nigra pars compacta dopaminergic neurons and their nigrostriatal projection. This is the key conformance target of the module: motor parkinsonism emerges once nigral dopaminergic loss removes nigrostriatal dopamine input below a compensable threshold. Conforming disorders substitute their specific upstream driver while sharing this nigrostriatal degeneration.
Downstream
-
Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
Loss of the nigrostriatal projection depletes striatal dopamine and unbalances the basal ganglia motor circuit.
Show evidence (2 references)
"dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations."
Confirms dopaminergic neuronal loss in the substantia nigra pars compacta as the core pathological lesion of parkinsonian neurodegeneration.
"Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."
States that substantia nigra neuronal loss causes striatal dopamine deficiency, supporting the edge from nigral degeneration to the downstream striatal/circuit node.
Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
effector
Loss of nigrostriatal dopaminergic terminals depletes dopamine in the striatum, the principal input nucleus of the basal ganglia. Reduced striatal dopamine shifts the basal ganglia-thalamocortical motor circuit toward excessive inhibitory output (hyperactive indirect pathway, hypoactive direct pathway), producing the cardinal features of parkinsonism (HP:0001300) — bradykinesia, rigidity, and rest tremor. In the dopaminergic parkinsonisms this circuit deficit is levodopa-responsive; manganism is a partial exception with predominantly pallidal pathology and poor levodopa response.
Show evidence (3 references)
"Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease."
Identifies striatal dopamine deficiency as a defining neuropathological hallmark, the proximate biochemical deficit of this node.
"Dopaminergic depletion in Parkinson's disease disrupts the corticostriatal balance leading to increased activity the indirect circuit and reduced activity in the direct circuit."
Describes how striatal dopamine loss unbalances the direct and indirect basal ganglia pathways, the circuit basis of parkinsonian motor signs.
"In the parkinsonian state, dopamine depletion shifts the BG toward inhibiting cortically generated movements by increasing the gain in the globus pallidus pars externa-subthalamic nucleus-globus pallidus pars interna network"
Mechanistically links dopamine depletion to excessive basal ganglia inhibitory output that suppresses movement, supporting parkinsonism as the circuit-level endpoint of the module.